Login to Your Account



Abraxis Reports Good NSCLC Results; Pancreatic Data Pending

By Catherine Hollingsworth


Thursday, March 18, 2010
Abraxane combined with carboplatin was shown to be superior to Taxol plus carboplatin in terms of overall response rate in a Phase III study in patients with non-small-cell lung cancer (NSCLC), Abraxis BioScience Inc. reported. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription